Shanghai Mental Health

Olanzapine is a small-molecule D2-like dopamine receptor antagonist indicated for schizophrenia. The Shanghai Mental Health Center is conducting clinical research under internal code CRC2017ZD03, with the program currently in Phase 3 development status as of the latest milestone on 2025-04-08. Olanzapine is a well-established antipsychotic with extensive global regulatory approvals across the United States, European Union, Japan, Australia, and China. The compound is available in multiple formulations and routes of administration, including oral and intramuscular delivery. Multiple generic and branded versions are marketed internationally by numerous sponsors including Eli Lilly, Teva, Sandoz, Apotex, and others. The Shanghai Mental Health Center's Phase 3 program represents ongoing clinical evaluation in the Chinese market, where olanzapine remains in active clinical trials. The drug has demonstrated efficacy in dopamine D2 receptor antagonism, a well-validated mechanism for antipsychotic activity in schizophrenia management.

Schizophrenia remains a significant global health burden affecting approximately 20 million people worldwide, with substantial unmet medical needs in treatment optimization, tolerability, and patient outcomes. Olanzapine represents a cornerstone antipsychotic therapy with decades of clinical experience and established efficacy-safety profiles. The competitive landscape includes multiple dopamine antagonists and serotonin receptor modulators, yet dopamine D2 antagonism remains a primary therapeutic strategy. The Shanghai Mental Health Center's Phase 3 program reflects ongoing clinical development in China, a market with growing psychiatric treatment demand and regulatory focus on antipsychotic efficacy and safety. Olanzapine's market relevance is sustained by its broad approval status, multiple formulations addressing different patient populations, and continued use in first-line and maintenance schizophrenia treatment. The intramuscular formulation addresses adherence challenges in severe psychotic disorders. Commercial significance is underscored by the extensive generic competition in developed markets and continued branded presence in emerging markets, particularly China where the Shanghai Mental Health Center program is active.

Drug Class: Atypical antipsychotic (second-generation antipsychotic)

Mechanism of Action: D2-like dopamine receptor antagonist

Molecular Target: D2-like dopamine receptor

Modality: Small molecule

Routes of Administration: Oral (tablet, orally disintegrating tablet) and intramuscular injection

Therapeutic Class: Nervous system agents (ATC N05)

Related Therapies: Other atypical antipsychotics including risperidone (APO-RISPERIDONE), lurasidone (APO-LURASIDONE), and aripiprazole (ABILIFY); alternative mechanisms include serotonin 2a receptor antagonists (INVEGA, SAPHRIS, REXULTI) and melatonin receptor agonists (HETLIOZ)

First Approval: Olanzapine was approved in the United States (NDA020592, NDA021086, NDA021253) and subsequently in Australia (first listed 2000-08-01), European Union (multiple EMA product numbers including EMEA/H/C/000114), and Japan (December 2017)

Patent Status: Not yet disclosed in the facts provided

United States (FDA): Olanzapine is approved with multiple NDA and ANDA applications (NDA020592, NDA021086, NDA021253, NDA213378, and numerous ANDA applications from 35+ manufacturers including Ajanta Pharma, Alkem Labs, Apotex, Aurobindo, Dr. Reddy's Labs, Sandoz, Sun Pharma, Teva, and others). Evidence available via FDA Orange Book.

European Union (EMA): Approved with 13 EMA product numbers (EMEA/H/C/000114 through EMEA/H/C/001088) across multiple marketing authorization holders including Eli Lilly, Apotex Europe BV, Cipla (EU) Limited, Glenmark, Krka, Teva B.V., and Viatris Limited. Authorisation dates range from 2026-05-07 to 2026-05-11.

Japan (PMDA): Approved as of December 2017.

Australia (TGA): Approved with multiple PBS codes (3381Y, 3382B, 3384D, 3385E, 8170B, 8185T, 8186W, 8187X, 8433W, 8434X) across sponsors including Alphapharm Pty Ltd, Apotex Pty Ltd, Arrow Pharma Pty Ltd, Pharmaco (Australia) Limited, and Sandoz Pty Ltd. First listed 2000-08-01.

China (NMPA): Olanzapine is in clinical trials status in China, with three active NCT-registered trials (NCT02850445, NCT03510325, NCT04437017). The Shanghai Mental Health Center's Phase 3 program (CRC2017ZD03) represents ongoing clinical evaluation in this market.

Strategic Implications: The Shanghai Mental Health Center's Phase 3 program reflects continued clinical development of olanzapine in China, a market with expanding psychiatric treatment demand and regulatory focus on antipsychotic efficacy and safety. This program may support regulatory approval or label expansion in the Chinese market, where olanzapine currently remains in clinical trial status despite approvals in Western markets.

Competitive Implications: Olanzapine maintains competitive positioning through its established clinical profile, multiple formulations, and intramuscular option for adherence-challenged patients. However, the market includes diverse mechanisms (dopamine antagonists, serotonin modulators, melatonin agonists) and extensive generic competition in developed markets. The Phase 3 program in China positions olanzapine for potential branded market presence in an emerging market with growing psychiatric treatment adoption.

Future Catalysts: Completion of the Shanghai Mental Health Center Phase 3 program (expected milestone timing not yet disclosed) may trigger regulatory submissions or approvals in China. Clinical trial results from NCT03510325 and related trials (NCT02850445, NCT04437017) represent key data catalysts. Regulatory decisions from NMPA regarding olanzapine formulations or indications represent potential milestones.

Expected Milestones: Phase 3 completion and data readout timing not yet disclosed. Regulatory submission or approval decision in China represents the anticipated next milestone, though specific dates are not yet disclosed.